{"nctId":"NCT01086969","briefTitle":"A Study of Meningococcal Vaccine, Menactra® in Healthy Subjects in India","startDateStruct":{"date":"2010-06"},"conditions":["Meningococcal Infection","Meningitis"],"count":300,"armGroups":[{"label":"Study Group","type":"EXPERIMENTAL","interventionNames":["Biological: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate (Menactra®)"]}],"interventions":[{"name":"Meningococcal Polysaccharide Diphtheria Toxoid Conjugate (Menactra®)","otherNames":["Menactra®"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria :\n\n* Aged 2 to 11 years or Aged 12 to 17 years or Aged 18 to 55 years of age on the day of inclusion\n* For participants aged 2 to 11 years: Provision of informed consent form signed by the parent(s) or legal representative.\n* For participants aged 12 to 17 years: Provision of assent form signed by the participant and informed consent form signed by the parent(s) or legal representative.\n* For participants aged 18 to 55 years: Provision of informed consent form signed by the participant. If the participant or the participant's parents or legally accepted representative (participants aged 2 to 17 years) are illiterate, an independent witness is required to sign the consent form.\n* Participant and parent/legally acceptable representative (if applicable) able to attend all scheduled visits and comply with all trial procedures\n* For a woman of child-bearing potential, sexually active, use of a medically acceptable and effective method of contraception for at least 4 weeks prior to vaccination, until at least 4 weeks after vaccination (not applicable for participants aged 2 to 17 years' females not of child-bearing potential or not sexually active)\n\nExclusion Criteria :\n\n* For a woman of child-bearing potential sexually active, known or suspected pregnancy or positive serum/urine pregnancy test (not applicable for participants aged 2 to 17 years' females not of child-bearing potential or not sexually active)\n* Breast-feeding woman\n* Participation in another clinical trial investigating a vaccine, drug, medical device, or a medical procedure in the 4 weeks preceding the trial vaccination\n* Planned participation in another clinical trial during the present trial period\n* Known or suspected congenital or acquired immunodeficiency, immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months, or long-term systemic corticosteroids therapy\n* Known systemic hypersensitivity to any of the vaccine components or history of a life-threatening reaction to the trial vaccine or to a vaccine containing any of the same substances\n* Chronic illness, at a stage that could interfere with trial conduct or completion, in the opinion of the investigator\n* Current alcohol abuse or drug addiction that may interfere with the subject's ability to comply with trial procedures\n* Receipt of blood or blood-derived products in the past 3 months, that might interfere with the assessment of immune response\n* Receipt or planned receipt of any vaccine (other than influenza vaccine which can be given 2 weeks or more before vaccination) in the 4 weeks preceding or following the trial vaccination\n* Known Human Immunodeficiency Virus (HIV), Hepatitis B surface (HBs) antigen , or Hepatitis C seropositivity as reported by the participant/parent/guardian and/or based on medical history\n* History of documented invasive meningococcal disease\n* Previous vaccination against meningococcal disease with either the trial vaccine or another vaccine\n* Thrombocytopenia, bleeding disorder or anticoagulants in the 3 weeks preceding inclusion contraindicating intramuscular vaccination\n* Subjects deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized without his/her consent\n* Personal or family history of Guillain-Barré Syndrome\n\nTemporary contraindications delaying vaccination until resolved:\n\n* Febrile illness (temperature ≥38.0°C) or moderate or severe acute illness/infection on the day of vaccination\n* Received oral or injected antibiotic therapy within the 72 hours prior to any blood draw","healthyVolunteers":true,"sex":"ALL","minimumAge":"2 Years","maximumAge":"55 Years","stdAges":["CHILD","ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Vaccine Antibody Titers at ≥ 8 Before and After Menactra Vaccination","description":"Antibodies to Menactra vaccine were measured by the Serum bactericidal assay baby rabbit complement (SBA BR) Test.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null},{"groupId":"OG001","value":"27","spread":null},{"groupId":"OG002","value":"23","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"95","spread":null},{"groupId":"OG001","value":"94","spread":null},{"groupId":"OG002","value":"97","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24","spread":null},{"groupId":"OG001","value":"43","spread":null},{"groupId":"OG002","value":"66","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"91","spread":null},{"groupId":"OG001","value":"95","spread":null},{"groupId":"OG002","value":"99","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"92","spread":null},{"groupId":"OG001","value":"92","spread":null},{"groupId":"OG002","value":"89","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99","spread":null},{"groupId":"OG001","value":"97","spread":null},{"groupId":"OG002","value":"98","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"54","spread":null},{"groupId":"OG001","value":"68","spread":null},{"groupId":"OG002","value":"52","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"96","spread":null},{"groupId":"OG001","value":"97","spread":null},{"groupId":"OG002","value":"99","spread":null}]}]}]},{"type":"PRIMARY","title":"Serum Bactericidal Assay Baby Rabbit Complement (SBA BR) Geometric Mean Titers Before and Post Menactra Vaccination","description":"Antibodies to Menactra antigens determined by the serum bactericidal assay baby rabbit complement (SBA-BR) test.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.51","spread":null},{"groupId":"OG001","value":"15.0","spread":null},{"groupId":"OG002","value":"9.78","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1145","spread":null},{"groupId":"OG001","value":"1324","spread":null},{"groupId":"OG002","value":"2261","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.92","spread":null},{"groupId":"OG001","value":"17.9","spread":null},{"groupId":"OG002","value":"56.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"610","spread":null},{"groupId":"OG001","value":"2343","spread":null},{"groupId":"OG002","value":"7486","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"355","spread":null},{"groupId":"OG001","value":"309","spread":null},{"groupId":"OG002","value":"156","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1964","spread":null},{"groupId":"OG001","value":"3190","spread":null},{"groupId":"OG002","value":"3926","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31.3","spread":null},{"groupId":"OG001","value":"47.8","spread":null},{"groupId":"OG002","value":"28.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1756","spread":null},{"groupId":"OG001","value":"2538","spread":null},{"groupId":"OG002","value":"3183","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With at Least a 4-fold Increase in Antibodies to Menactra Vaccine Antigens Post Vaccination","description":"Antibodies to Menactra antigens determined by the serum bactericidal assay baby rabbit complement (SBA-BR) test.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"85","spread":null},{"groupId":"OG001","value":"85","spread":null},{"groupId":"OG002","value":"96","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"88","spread":null},{"groupId":"OG001","value":"91","spread":null},{"groupId":"OG002","value":"96","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"68","spread":null},{"groupId":"OG001","value":"75","spread":null},{"groupId":"OG002","value":"89","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"93","spread":null},{"groupId":"OG001","value":"96","spread":null},{"groupId":"OG002","value":"97","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants Reporting a Solicited Injection Site or Systemic Reactions Following Menactra Vaccination","description":"Solicited injection site: Pain, Erythema (Redness), and Swelling. Solicited Systemic reaction: Fever (Temperature), Headache, Malaise, and Myalgia","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30","spread":null},{"groupId":"OG001","value":"23","spread":null},{"groupId":"OG002","value":"38","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"19","spread":null},{"groupId":"OG002","value":"19","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"13","spread":null},{"groupId":"OG002","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"8","spread":null},{"groupId":"OG002","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":100},"commonTop":["Injection site pain","Headache","Myalgia","Malaise","Fever"]}}}